



Universitätsklinikum
Hamburg-Eppendorf

European
ScreeningPort

Biomarker and Translational Drug Discovery Workshop

1st September, 2011 (Campus Forschung/UKE, N27, Seminar Room 14)

14.00-14.10: Introduction of the European ScreeningPort and the UKE Biomarker Platform (Dr. Philip Gribbon (philip.gribbon@screeningport.com) and Dr. Ole Pless (ole.pless@screeningport.com), European ScreeningPort)

14.10-14.25: Dr. Thomas Krahn (thomas.krahn@bayer.com), Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Global Biomarker Research
“Biomarker Strategy in Oncology Drug Development”

14.30-14.45: Prof. Dr. Dr. Christian Betzel (Christian.Betzel@uni-hamburg.de), University of Hamburg, Institute of Biochemistry and Molecular Biology, Laboratory for Structural Biology of Infection and Inflammation c/o DESY:
“Latest Approaches in Structure Based Drug Discovery“

14.50-15.05: Dr. Kristoffer Weber (k.weber@uke.uni-hamburg.de), University of Hamburg, RG Prof. Dr. Fehse, Clinic for Stem Cell Transplantation, Department Cell and Gene Therapy, UKE:
“High Throughput Screening for HIV inhibiting drugs”

15.10-15.25: Dr. Gabriele Loers (gabriele.loers@zmnh.uni-hamburg.de), University of Hamburg, RG Prof. Dr. Schachner, Institute for the Biosynthesis of Neural Structures, ZMNH/UKE:
“Translational Drug Discovery - Identification of Novel Inhibitors and Enhancers of Nervous System Regeneration”

15.30-15.45: Coffee break

15.45-16.00: Dr. Sabine Lange (slange@mesoscale.com), Mesoscale Discovery, Gaithersburg, USA:
“Applications of Meso Scale Discovery plate-based Electrochemiluminescent Assays”

16.05-16.20: Hannieh Sotoud (h.sotoud@uke.uni-hamburg.de), University of Hamburg, RG
Prof. Dr. Eschenhagen, UKE:

"Small molecule screen for Phosphatase 1 Inhibitor-1 antagonists"

16.25-16.40: Prof. Dr. Roland Martin (roland.martin@zmnh.uni-hamburg.de;
Roland.Martin@usz.ch) / Dr. Wolfgang Faigle (wolfgang.faigle@usz.ch), University Hospital
Zürich, Department of Clinical Neuroimmunology and Multiple Sclerosis Research:

"Biomarkers in Multiple Sclerosis"

16.45: Concluding remarks and refreshments